CRDL

Cardiol Therapeutics Inc. Class A · NASDAQ

Sector Health Technology
Industry Biotechnology
Website cardiolrx.com
Employees(FY) -
ISIN CA14161Y2006

Performance

-0.5%

1W

+5.26%

1M

+65.29%

3M

+138.1%

6M

+137.19%

YTD

+250.57%

1Y

Profile

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx for patients hospitalized with COVID-19, as well as for the treatment of recurrent pericarditis and acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.

Advanced Technical Analysis

Technical Analysis of CRDL 2024-05-03

Overview:

In analyzing the technical indicators for CRDL over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key indicators, we aim to offer valuable insights and predictions for informed deci...

See more ...

Recent News & Updates

2024-04-01 21:53
CRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q4 2023(Investorplace)
2024-04-01 18:00
Cardiol Therapeutics Announces Year-End 2023 Update on Operations(Newsfilecorp)
2024-03-04 07:28
11 Best Small Cap Pharma Stocks to Invest In(Insidermonkey)
2024-02-20 18:27
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis(Newsfilecorp)
2024-02-14 18:27
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis(Newsfilecorp)
2024-01-23 18:27
Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market(Newsfilecorp)
2024-01-08 18:27
Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis(Newsfilecorp)
2023-12-04 18:27
Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot(Newsfilecorp)
2023-11-15 16:30
Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases(Newsfilecorp)
2023-10-31 19:27
Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis(Newsfilecorp)
2023-10-20 05:00
Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement(Newsfilecorp)
2023-10-12 21:24
Cardiol Therapeutics (NASDAQ: CRDL)Advancements in Therapies for Inflammatory Heart Diseases(Yahoo Finance)
2023-10-11 01:05
Cardiol Therapeutics releases positive study results of subcutaneously administered cannabidiol(Yahoo Finance)
2023-10-09 18:00
Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fraction(Newsfilecorp)
2023-09-26 21:34
Here's Why You May Invest in Cardiol Therapeutics (CRDL) Stock(Zacks)
2023-09-25 19:27
Cardiol Therapeutics to Present at Cantor Fitzgerald 2023 Global Healthcare Conference(Yahoo Finance)
2023-09-18 19:27
Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx(TM) for the Treatment of Acute Myocarditis(Yahoo Finance)
2023-08-08 19:27
Cardiol Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conference(Yahoo Finance)
2023-08-07 19:27
Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market(Yahoo Finance)
2023-06-28 22:19
Cardiol Therapeutics Reports Results of 2023 Annual General Meeting(Yahoo Finance)
2023-06-26 19:27
Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4:30 p.m. EDT(Yahoo Finance)
2023-05-08 19:15
Sidoti's Micro-Cap Virtual May Conference(Yahoo Finance)
2023-03-28 19:27
Cardiol Therapeutics Announces Year-End 2022 Update on Operations(Yahoo Finance)
2023-03-06 18:27
Cardiol Therapeutics Announces Study Results from Collaborating Research Center Demonstrating Cardioprotective Effects of Cannabidiol in a Model of Heart Failure(Yahoo Finance)
2023-01-17 01:59
Cardiol Therapeutics says first patient enrolled in Phase 2 study of CardiolRx for Pericarditis(Yahoo Finance)
2023-01-16 18:27
Cardiol Therapeutics Announces First Patient Enrolled in Phase II Study Evaluating CardiolRx(TM) for the Treatment of Recurrent Pericarditis(Yahoo Finance)
2022-12-11 18:27
Cardiol Therapeutics Commences Multi-Center Phase II Pilot Study of CardiolRx(TM) for the Treatment of Recurrent Pericarditis(Yahoo Finance)
2022-11-14 04:00
Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement(Yahoo Finance)
2022-11-06 18:27
Cardiol Therapeutics Announces Study Results Demonstrating Protective Effects of CardiolRx(TM) in a Model of Acute Pericarditis(Yahoo Finance)
2022-10-24 18:30
Cardiol Therapeutics Prioritizes Phase II Clinical Programs in Underserved Heart Diseases(Yahoo Finance)

Page 1 of 2

previousnext